1148 results about "Glycollic acid" patented technology

A method of the preparation and utilization of polymerized alpha-hydroxycarboxylic-acid-coated proppants for gravel pack and removal of filter cake that was deposited by reservoir drilling fluid. In a preferred example, polyglycolic-acid-coated sand is used to replace conventional gravel pack sand typically used for gravel packing. Under downhole conditions, the acidic by-product generated from the hydration of polyglycolic-acid-coated sand can break down acid-soluble and/or acid-breakable components embedded in the filter cake. This reaction enhances the filter cake removal and the flow of hydrocarbon from the producing formation. The polyglycolic-acid-coated sand may be produced by polymerizing a glycolic acid with a natural or synthetic proppant like 20-40 mesh commercial sand, at temperatures of about 210° F. or higher.

The present invention provides bioactive polymer compositions that can be formulated to release a wound healing agent at a controlled rate by adjusting the various components of the composition. The composition can be used in an external wound dressing, as a polymer implant for delivery of the wound healing agent to an internal body site, or as a coating on the surface of an implantable surgical device to deliver wound healing agents that are covalently attached to a biocompatible, biodegradable polymer and/or embedded within a hydrogel. Methods of using the invention bioactive polymer compositions to promote natural healing of wounds, especially chronic wounds, are also provided. Examples of biodegradable copolymer polyesters useful in forming the blood-compatible, hydrophilic layer or coating include copolyester amides, copolyester urethanes, glycolide-lactide copolymers, glycolide-caprolactone copolymers, poly-3-hydroxy butyrate-valerate copolymers, and copolymers of the cyclic diester monomer, 3-(S)[(alkyloxycarbonyl)methyl]-1,4-dioxane-2,5-dione, with L-lactide. The glycolide-lactide copolymers include poly(glycolide-L-lactide) copolymers formed utilizing a monomer mole ratio of glycolic acid to L-lactic acid ranging from 5:95 to 95:5 and preferably a monomer mole ratio of glycolic acid to L-lactic acid ranging from 45:65 to 95:5. The glycolide-caprolactone copolymers include glycolide and ε-caprolactone block copolymer, e.g., Monocryl or Poliglecaprone.

The invention is directed to modified polymers with increased drug-loading including compounds of formula (I): wherein Z is a poly(lactic-co-glycolic acid) (PLGA) polymer having molecular weight from 1-15 kDa and where the ratio of lactide to glycolide in the PLGA polymer is from 1:10 to 10:1; formula (II) R₁ are independently H, R₂, OH, O-alkyl, —O—R₂, NH—R₂, -linker-R₂, or -and R₂ are independently one or more therapeutic agents. The invention is also directed to nanoparticle drug delivery systems including a PLGA-b-PEG block copolymer; and a stabilizer and to drug delivery systems including PLGA-b-PEG block copolymer polyvinyl alcohol (PVA) nanoparticle; and the modified polymer substantially as described herein.

A mixed micellar aerosol pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal lauryl sulphate, at least three micelle forming compounds, a phenol and a propellant. The micelle forming compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanyl glycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof. The amount of each micelle forming compound is present in a concentration of from 1 to 20 wt./wt. % of the total formulation, and the total concentration of micelle forming compounds are less than 50 wt./wt. % of the formulation. The propellant, e.g. a fluorocarbon propellant, provides enhanced absorption of the pharmaceutical agent.

An implantable tissue grafting medical system and material using a combination of bio-absorbable and non bio-absorbable fibers and materials such as Poly Glycolic Acid (PGA) and polyester (PET), provides a permeable mesh or weave of fibers with an initial interstice size and permeability factor suitable to initial implant requirements, and a pre-engineered bio-absorption pattern and rate that controls the gradual expansion of interstice size within the mesh or weave in one or two dimensions up to a pre-engineered maximum interstice size, consistent with the anticipated rate of tissue regeneration on the implant, while retaining a primary grid or circumferential pattern of non-absorbable fibers at the maximum interstice size for supporting the new tissue for an extended period. Various means for combining materials to obtain initial interstice size, pattern and permeability, with the desired absorption pattern and rate, and the desired end point interstice size and spacing, are also disclosed.

A new embolic agent, bioabsorbable polymeric material (BPM) is incorporated to a Guglielmi detachable coil (GDC) to improve long-term anatomic results in the endovascular treatment of intracranial aneurysms. The embolic agent, comprised at least in part of at least one biocompatible and bioabsorbable polymer and growth factors, is carried by hybrid bioactive coils and is used to accelerate histopathologic transformation of unorganized clot into fibrous connective tissue in experimental aneurysms. An endovascular cellular manipulation and inflammatory response are elicited from implantation in a vascular compartment or any intraluminal location. Thrombogenicity of the biocompatible and bioabsorbable polymer is controlled by the composition of the polymer. The coil further is comprised at least in part of a growth factor or more particularly a vascular endothelial growth factor, a basic fibroblast growth factor or other growth factors. The biocompatible and bioabsorbable polymer is in the illustrated embodiment at least one polymer selected from the group consisting of polyglycolic acid, poly~glycolic acid/poly-L-lactic acid copolymers, polycaprolactive, polyhydroxybutyrate/hydroxyvalerate copolymers, poly-L-lactide. Polydioxanone, polycarbonates, and polyanhydrides.

The invention provides a stretch blow molded container formed from a thermoplastic resin material which comprises polyglycolic acid having (a) a repeating unit represented by the following formula (1): (b) a melt viscosity, eta * [as measured at a temperature of (the melting point, Tm of the polymer+20 DEG C.) and a shear rate of 100/sec] of 500-100,000 Pa.s; (c) a melting point, Tm of at least 180 DEG C.; (d) a melt enthalpy, DELTA Hm of at least 20 J/g; and (e) a density of at least 1.50 g/cm3 as measured in an unoriented, crystallized form, wherein the stretch blow molded container has tensile strength (in a circumferential direction) of at least 100 MPa and a carbon dioxide permeability (as measured at a temperature of 23 DEG C. and 80% relative humidity; in terms of the thickness of 50 mu m) of 300 cc/m2.day.atm or smaller at the body sidewall thereof, and a production process thereof.

The invention relates to a method for preparing composite biological medical material used to avoid adhering organisms, wherein said film is formed by two layers; the layer used as base material is formed by degradable composite macromolecule polylactic acid, glycolic acid, or their copolymer, treated by static spin technique, to make film fiber into nanometer level; then coats one layer of degradable natural macromolecule chitose or relative derivant on the base film, to be treated to obtain the degradable composite biological medical film; and the invention can add different amounts of medical elasticizer between two layers to adjust the degrade speed. The invention can improve immunity with haemostasis function, etc.

Drug-containing nanoparticles are provided that enable effective targeting and sustained-release of a water-soluble, non-peptide, low-molecular weight drug and cause reduced accumulation of the drug in the liver. The nanoparticles containing a water-soluble, non-peptide, low-molecular weight drug are obtained by hydrophobicizing the water-soluble, non-peptide, low-molecular weight drug by a metal ion, and reacting the hydrophobicized drug with a poly(lactic acid)-polyethylene glycol block copolymer or a poly(lactic-co-glycolic acid)-polyethylene glycol block copolymer. The nanoparticles have favorable targeting and sustained-release properties and cause reduced accumulation of the drug in the liver.

The invention discloses a tissue induction biomedical material, and particularly relates to a degradable active biological membrane/powder. The tissue induction biomedical material is prepared from, by weight, 0.1-99% of degradable medical polyurethane, 0-99.9% of polyhydroxyalkanoate, 0-99.9% of polylactic acid and 1-99.9% of collagen, wherein polyhydroxyalkanoate is one of PHA, PHB, PHBV, PHBHHx and P3HB4HB, polylactic acid is one of polyglycolic acid and polylactic acid-glycolic acid copolymer, and collagen is one or more of collagen I, collagen II, collagen VI, collagen IX, collagen X, collagen XI and other various in-vivo collagen. The ratio of all the components is adjusted according to the requirements of the implanting positions of different in-vivo tissue for material performance, degradation products and PH values, so better clinical service is provided.

The invention discloses an Exenatide release microsphere preparation mainly comprising the following components in percentage by weight: 0.5-10 percent of Exenatide and 85-99 percent of polylactic acid-glycolic acid copolymer. The invention also discloses a preparation method and an application of the Exenatide release microsphere preparation. The Exenatide release microsphere preparation not onlycan prolong the action time of the Exenatide in the body and reduce the medicine application frequency, but also can maintain the effective blood-medicine concentration of the Exenatide and improve the treatment effect.

Formulations for controlled, sustained release of biologically active agents for the treatment of ocular disorders have been developed. These formulations are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof. The microparticles are characterized by low burst levels and efficient drug loading and sustained release.

The invention discloses a method for producing polymer grade ethylene glycol and co-producing methyl glycolate, which comprises the following steps that: feed gas produced by taking coal, natural gas or residual oil as a raw material is subjected to purification treatment to obtain carbon monoxide and hydrogen through pressure varying absorption; the carbon monoxide, the hydrogen and auxiliary raw materials, namely industrial methanol, oxygen and nitrogen oxide are subjected to processes such as nitrosation reaction, carbonylation reaction, hydrogenation reaction, rectification separation, tail gas purification treatment and the like to obtain the ethylene glycol and the methyl glycolate; and the yield proportion of the ethylene glycol and the glycollic acid can be adjusted by controlling the hydrogenation reaction and the rectification process. In the method, the carbonylation reaction is performed on a Pd/alpha-Al2O3 catalyst added with two additives, and the carbonylation reaction is performed on a Cu-SiO2 or Cu-Cr2O3 or Cu-Zn-Al methanol catalyst, wherein the conversion ratio of the CO and the H2 is over 99.9 percent; and the selectivity is over 98 percent. Compared with the prior method for producing the ethylene glycol and the methyl glycolate, the method has the characteristics of low cost and high benefit.

The invention relates to a preparation method of a biodegradable diaphragm for promoting regeneration of periodontal tissue, belonging to the field of biological regeneration medicine. In the invention, polylactic acid, polycaprolactone, polylactic acid-glycollic acid copolymer, collagen, modified chitosan and other biodegradable synthetic polyester polymers or natural biodegradable high molecular materials are used as raw materials to prepare a thin-film material with a nano structure through the electrostatic spinning process, and then, various growth factors are loaded on the thin-film material through the supermolecule loading technology. The diaphragm for reparative regeneration of the periodontal tissue, which is prepared by the method of the invention, has good biocompatibility and can realize the purposes of inhibiting inflammation and inducing regeneration of the periodontal tissue through the controlled release of the loaded growth factors.

The invention provides a long-acting microsphere injection as an antidiabetic medicament, the long-acting microsphere injection comprises liraglutide, PLGA (poly(lactic-co-glycolic acid)), excipients and a surfactant, and the invention simultaneously relates to a preparation method of the injection. Liraglutide long-acting sustained-release microspheres provided by the invention are designed to perform subcutaneous injection once every 28 days, thereby greatly reducing treatment burden on a patient, improving medication compliance and reducing treatment cost; simultaneously, results of in vitro release studies, animal experiments and the like prove that the obtained sustained-release microspheres can slowly release a medicament for a long time in vitro and in vivo.

The present invention discloses a low cost bio-based full degradable film and preparation method thereof, the ratio of each component in parts by mass of the film is as follows: 15-25 parts of a polyglycolic acid, 25-35 parts of corn starch, 35-55 parts of poly(butylene adipate-co-terephthalate), 5 parts of a compatilizer, 3.75-12.25 parts of a starch plasticizer, 0.5-0.7 part of citric acid, 0.75-1.25 parts of acetyl tributyl citrate, 0.3-0.5 part of maleic anhydride, 0.2 part of antioxidant 164, and 0.2 part of 2-(2″-hydroxyl-5″-methylphenyl)benzotriazole. The low cost bio-based full degradable film provided by the present invention has a bio-based content, which can reach 30% or more, a lower cost, and a tensile strength exceeding a traditional PE thin film, and has very important significance for solving the problem of “white pollution” and promoting the popularization and application of full biodegradable materials.